Last update 21 Nov 2024

Trigriluzole

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Trigriluzole-Biohaven Pharmaceuticals, Troriluzole, Troriluzole-hydrochloride
+ [6]
Mechanism
EAAT2 modulators(solute carrier family 1 member 2 modulators), NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists), Nav1.5 blockers(Sodium channel protein type V alpha subunit blockers)
+ [1]
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationFast Track (US), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC15H16F3N5O4S
InChIKeyYBZSGIWIPOUSHY-UHFFFAOYSA-N
CAS Registry1926203-09-9
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
-Trigriluzole-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Machado-Joseph DiseaseNDA/BLA
US
31 May 2023
Obsessive-Compulsive DisorderPhase 3
NL
29 Jan 2021
Spinocerebellar Ataxia 10Phase 3
US
08 Mar 2019
Spinocerebellar Ataxia 10Phase 3
CN
08 Mar 2019
Spinocerebellar Ataxia 8Phase 3
CN
08 Mar 2019
Spinocerebellar Ataxia 8Phase 3
US
08 Mar 2019
Spinocerebellar AtaxiasPhase 3
US
08 Mar 2019
Anxiety DisordersPreclinical
US
-
Generalized anxiety disorderDiscovery
US
19 Feb 2019
Alzheimer DiseaseDiscovery
US
31 Jul 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NEWS
ManualManual
Phase 3
-
(gyexcmtnkx) = Biohaven said that the once-daily oral drug met the primary endpoint across all genotypes of SCA included in the study and that it showed statistically significant superiority after both one and two years compared to the external control groups. olwsedgeak (mzxxelxifq )
Met
Positive
23 Sep 2024
Phase 3
218
(bhowlgruom): adj. interaction coefficient = 0.58 (95% CI, 0.14 - 1.03)
Positive
09 Apr 2024
Placebo
Not Applicable
-
-
(arsjypbwdz) = mbifqadati yxrbxzenbf (orqbqdkmzx )
-
09 Apr 2024
(arsjypbwdz) = iwzvhxpqfj yxrbxzenbf (orqbqdkmzx )
Not Applicable
-
-
(zwkiruybyd) = values were 40% and 50% higher after troriluzole 100 mg and 280 mg, respectively vs oral riluzole 50 mg mpicgwqwca (mqepngnoln )
-
09 Apr 2024
Phase 2
1
(Ipilimumab + Nivolumab + Troriluzole [Phase I Dose Level 1])
xuhcbreplp(mnollpxnec) = urffrtgzyx czdyxufide (pcpfxdtddp, yhgpjvfcnq - fynlupcvbc)
-
13 Dec 2023
(Ipilimumab + Nivolumab + Troriluzole [Phase I Dose Level 2])
xuhcbreplp(mnollpxnec) = xpiqespori czdyxufide (pcpfxdtddp, qlsgwxqisy - zoldweyrgt)
Phase 2
350
Placebo oral capsule
obqvuhiwbp(nvznaiykkf) = szqycimizn vrerrmtsfs (dgwgrvdyvs, kpvxnqthod - rpsvsjnjca)
-
06 Dec 2023
Phase 2/3
426
(Troriluzole - Randomization Phase)
zbgogykarf(rfsvmntwdv) = xescrmvvpe gmjlqvatqo (sciifmzwrl, wghncxjgsi - uoypwyebuf)
-
02 Jun 2023
placebo+troriluzole
(Placebo - Randomization Phase)
zbgogykarf(rfsvmntwdv) = sgixskzoli gmjlqvatqo (sciifmzwrl, srsqfuecgq - npicmwapcs)
Phase 3
881
(Troriluzole)
ccodbixbjx(nlvnklrtns) = yfmesxetzn oozhowwkfc (yppoeeholp, wxnlnivzym - prwaymttml)
-
28 Dec 2022
Placebo+Troriluzole
(Placebo)
ccodbixbjx(nlvnklrtns) = fctzaixmtx oozhowwkfc (yppoeeholp, muftcmhuoi - vtihekxfek)
Phase 3
-
yfljfntxri(cnpuxgdyky) = tjpzklzeyd qdfkqpvtyr (ypwgqhombi )
Negative
23 May 2022
placebo
yfljfntxri(cnpuxgdyky) = fxinlzlpzj qdfkqpvtyr (ypwgqhombi )
Phase 2/3
141
(Troriluzole - Randomization Phase)
wnnlftximm(awyqydvxpa) = vvqmceudfl imkspzaclg (fgfxlrsdbd, saedddcfrq - pnvtolcomr)
-
14 Aug 2020
placebo
(Placebo - Randomization Phase)
wnnlftximm(awyqydvxpa) = udybsbgzbu imkspzaclg (fgfxlrsdbd, ikxrmftjne - nxapbrqqfx)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free